Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: Norgine Pharmaceuticals Limited, Norgine House, Widewater Place, Moorhall Road, Harefield, Uxbridge, UB9 6NS, UK
Dantrium Capsules 25 mg.
| Pharmaceutical Form |
|---|
|
Hard capsule. Dantrium Capsules 25 mg are presented as white/orange capsules of size 3. |
Each capsule contains 25 mg dantrolene sodium.
Excipient with known effect: 161.0 mg of lactose monohydrate per capsule.
For a full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Dantrolene |
The receptor molecule for dantrolene has not been identified. Dantrolene inhibits the binding of ryanodine. Under some conditions, dantrolene will lower intra-sarcoplasmic calcium concentrations in the resting state. This may be more important in diseased muscle (e.g. In malignant hyperthermia in humans and swine stress syndrome) than in muscle with normal function. |
| List of Excipients |
|---|
|
Capsule content: Maize starch Capsule Shell: Gelatine |
Dantrium capsules are supplied in high density polyethylene (HDPE) bottles with HDPE caps. One bottle contains 100 capsules.
Norgine Pharmaceuticals Limited, Norgine House, Widewater Place, Moorhall Road, Harefield, Uxbridge, UB9 6NS, UK
PL 20011/0032
25 October 1989
| Drug | Countries | |
|---|---|---|
| DANTRIUM | Australia, Canada, Estonia, France, Ireland, Japan, Malta, Netherlands, New Zealand, Romania, United Kingdom, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
